Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 16/20 | 0.45 |
| ▸ | PPARG | P37231 | 11/20 | 0.41 |
| ▸ | PPARA | Q07869 | 11/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1746730 | 1.00 | PPARD (0.45) | PPARDPPARGPPARANR4A2RXRA | |
| SCHEMBL1747037 | 0.90 | PPARD (0.55) | PPARDPPARGPPARA | |
| SCHEMBL1744833 | 0.88 | PPARD (0.56) | PPARDPPARGPPARA | |
| SCHEMBL1744837 | 0.88 | PPARD (0.56) | PPARDPPARGPPARA | |
| SCHEMBL1813735 | 0.88 | PPARD (0.43) | PPARDPPARGPPARARARBRARG | |
| SCHEMBL1813736 | 0.88 | PPARD (0.43) | PPARDPPARGPPARARARBRARG | |
| SCHEMBL1744884 | 0.85 | TDP1 (0.41) | PPARDPPARGPPARANR4A2TSHR | |
| SCHEMBL1744882 | 0.85 | TDP1 (0.41) | PPARDPPARGPPARANR4A2TSHR | |
| SCHEMBL1746940 | 0.84 | PPARD (0.49) | PPARDPPARGPPARARARBRARG | |
| SCHEMBL1746938 | 0.84 | PPARD (0.49) | PPARDPPARGPPARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386540-A1 | Novel compounds, their preparation and use | High Point Pharmaceuticals, LLC (US) | 2011-11-16 | — | — | EP | disclosed |
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-10-06 | — | — | US | disclosed |
| US-7943613-B2 | Compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245244-A1 | PHENOXY ACETIC ACIDS AS PPAR DELTA ACTIVATORS | PPARG, PPARA, PPARD | PPARD 3/4885PPARG 1/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.